PLA2G7 Genotype

Your genes shape how much of a specific inflammation enzyme circulates in your blood, and that enzyme has been studied for decades as a possible driver of heart disease. PLA2G7 (the gene that codes for an enzyme called lipoprotein-associated phospholipase A2, or Lp-PLA2) holds the strongest known genetic influence on how much of this enzyme you carry.

Knowing your PLA2G7 variants will not give you a yes-or-no answer about your future heart attack risk. What it can do is help you understand a slice of your inherited biology that standard lipid panels miss, particularly if you have East Asian ancestry or a family history of early heart disease. This is a research-tier genetic test, and the result is most useful when interpreted alongside the enzyme activity level itself and your broader cardiovascular workup.

What This Gene Actually Controls

PLA2G7 is the genetic blueprint for Lp-PLA2, an enzyme made largely by inflammatory immune cells (macrophages) and carried through the bloodstream attached to cholesterol particles. Lp-PLA2 sits at the intersection of inflammation and artery wall damage, and its activity in the blood is partly inherited. Studies estimate that genetic factors account for about 41% of the variability in Lp-PLA2 activity and 25% of its mass, with PLA2G7 itself being the dominant single locus driving Lp-PLA2 mass. For Lp-PLA2 activity, the strongest genetic signal sits at a different locus near APOE/APOC1, which is a reminder that activity and mass are shaped by partly different sets of genes.

The variants in this gene fall into a few important groups. Some, like V279F, essentially switch the enzyme off. Others, like A379V and R92H, nudge enzyme levels up or down by smaller amounts. The clinical consequences of carrying these variants depend on which one you have, how many copies you carry, and your ancestry.

The V279F Loss-of-Function Variant

V279F is the most studied PLA2G7 variant. People who carry one copy retain roughly 60 to 75% of normal enzyme activity. People who carry two copies have essentially no Lp-PLA2 in their plasma, a condition called Lp-PLA2 deficiency. This variant is common in East Asian populations, found in about 12% of Koreans, and is rare in Europeans.

In one analysis, carrying minor alleles of V279F together with other variants was linked to a 37.8% reduction in Lp-PLA2 activity and a 41.6% reduction in enzyme mass. If your ancestry includes East Asian heritage, this is the variant most likely to meaningfully affect your enzyme level.

Other Coding Variants

A379V (also called rs1051931) shifts Lp-PLA2 activity in opposite directions depending on ancestry. In people of European descent, the minor allele was tied to about 7% higher enzyme activity. In Asian populations, the same allele was linked to lower activity. R92H is associated with decreased Lp-PLA2 activity, and several promoter region variants also nudge enzyme levels. These smaller-effect variants are why interpreting a PLA2G7 result is not as simple as reading a single line on a report.

Heart Disease Risk

This is where the story gets interesting and where many readers will be tripped up by surface-level explanations. The enzyme that PLA2G7 codes for, Lp-PLA2, is tied to heart disease in observational studies. People with higher Lp-PLA2 activity have a higher chance of developing coronary heart disease in unadjusted analyses. In one large meta-analysis, people in the top quarter of Lp-PLA2 activity had roughly 60% higher heart disease risk than people in the bottom quarter (unadjusted hazard ratio 1.61). After accounting for traditional risk factors like cholesterol, blood pressure, smoking, and diabetes, that signal shrank substantially (adjusted hazard ratio 1.17) and was no longer statistically significant, which is one of the reasons researchers debate whether the enzyme is a true driver of heart disease or mostly a marker of it.

You might assume that if you carry a PLA2G7 variant that lowers your enzyme level, your heart disease risk should drop too. The genetic data tells a more complicated story. In a meta-analysis that included more than 26,000 people of European ancestry across its analyses, PLA2G7 variants that modestly lowered enzyme activity were not associated with fewer heart disease events. A separate large study of five different Lp-PLA2-lowering alleles, covering more than 72,000 coronary heart disease cases and 110,000 controls, came to the same conclusion: none of the variants was tied to coronary heart disease.

Why the disconnect? The leading interpretation is that Lp-PLA2 activity is more of a risk marker than a causal driver of heart disease in most populations. The enzyme rides along with the inflammation and cholesterol particles that actually do the damage, so the level tracks risk without necessarily causing it. This is why drug companies developed an Lp-PLA2 inhibitor (darapladib) and saw it fail to prevent heart events in large trials.

The Korean Male Exception

One striking finding cuts against this picture. In a study of more than 8,000 South Korean men, carrying the V279F null allele was protective against coronary artery disease. Carriers had roughly 20% lower odds of coronary disease compared to non-carriers (combined odds ratio 0.80). This is the strongest evidence that lifelong absence of the enzyme may meaningfully reduce heart disease risk in at least some populations, and it is part of why this variant remains under active research.

How to reconcile the two findings: the same variant behaves differently in different ancestral and clinical contexts. The European studies tested modest-effect variants in mixed populations and found little signal. The Korean study tested a complete loss-of-function variant in a specific genetic background and saw a protective effect. PLA2G7 is not a simple good-allele bad-allele test, it is a window into a complex inflammation pathway whose impact depends on who you are.

Peripheral Artery Disease

In the Atherosclerosis Risk in Communities study, higher Lp-PLA2 activity was associated with greater risk of developing peripheral arterial disease (narrowing of blood vessels in the legs), though much of this risk was explained by traditional factors like smoking and diabetes. PLA2G7 variants themselves were not clearly tied to lower peripheral artery disease risk in the genetic data, mirroring the heart disease findings.

Aspirin Response

Two PLA2G7 variants (rs1051931 and rs7756935) have been linked to aspirin resistance in Chinese ischemic stroke patients on aspirin therapy. Carriers of a specific haplotype had higher platelet activity despite aspirin treatment, putting them at increased odds of aspirin resistance. This is an emerging finding from a relatively small study that may matter if you are on long-term antiplatelet therapy, particularly after a stroke.

Pain Sensitivity After Surgery

The rs1051931 variant has also been tied to postoperative pain. In a study of 635 surgical patients, people carrying two copies of the C allele had higher rates of dysesthesia (abnormal nerve sensations) and reported more intense pain on standardized scales. This is a preliminary finding from a single study, but if you are planning major surgery and want a fuller picture of why some people experience worse postoperative pain, this variant may be part of the answer.

What the Phenome-Wide Data Shows

A phenome-wide study of the V279F variant in approximately 90,000 Chinese adults looked across hundreds of disease categories. Lifelong lower Lp-PLA2 activity from this variant was not associated with major risk of vascular or non-vascular diseases after accounting for multiple comparisons. Weak signals appeared for diabetes and asthma but did not survive correction. The honest summary: for most people in most populations, carrying a PLA2G7 variant will not dramatically change your overall disease risk profile.

One-Time Result

PLA2G7 genotype is a fixed, inherited trait. Your variants do not change over your lifetime, and you do not need to repeat the test unless there is reason to question the original call. The lasting value of the result comes from how you use it to interpret other tests, particularly direct Lp-PLA2 activity measurements, and how it informs the cadence of your cardiovascular monitoring.

If your PLA2G7 result suggests reduced enzyme activity, you should pair the genotype with a direct Lp-PLA2 activity test to confirm what your blood enzyme level actually looks like. If your result is otherwise unremarkable, the value of the genotype is in ruling out a specific inherited explanation for unusual Lp-PLA2 readings later in life.

Decision Pathway for an Unexpected Result

If you carry V279F or another loss-of-function variant, the most useful next step is to order a direct Lp-PLA2 activity measurement so you can see the downstream phenotype. This combination of genotype plus activity gives a clearer picture than either alone. If your Lp-PLA2 activity is markedly low and you carry a known null variant, your lab readings on this enzyme are reliably low and not a sign of an acquired disease.

If you carry a variant linked to higher enzyme activity and your direct Lp-PLA2 activity is elevated, the conversation shifts to overall cardiovascular workup. Companion testing should include a full lipid particle analysis (ApoB and Lp(a)), a high-sensitivity inflammation marker (hs-CRP, or high-sensitivity C-reactive protein), and a coronary calcium scan if you are over 40 or have a family history of early heart disease. A cardiologist with a preventive focus, or a lipidologist, is the right specialist if the combined picture points to elevated atherosclerosis risk.

For biological family members, the rationale for testing depends on ancestry. The most clinically relevant variant, V279F, is common in East Asian populations. If you have East Asian heritage and you carry V279F, your siblings and children have a meaningful chance of carrying it too, and the genotype may be most useful in interpreting their Lp-PLA2 activity readings rather than predicting disease.

When Results Can Be Misleading

• Variant panel coverage: a typical PLA2G7 panel tests a handful of well-known variants. A negative result rules out only those specific variants, not every possible rare change in the gene.
• Ethnic-specific frequencies: the same variant can behave differently across ancestries. V279F is common in East Asians and rare in Europeans, and A379V shifts enzyme activity in opposite directions depending on background. Interpretation depends on which population the reference data came from.
• Genotype versus phenotype gap: your genotype predicts roughly how much enzyme you should produce, but day-to-day Lp-PLA2 activity is also shaped by lipid levels, inflammation, and other genes. A direct activity test gives the real-world number.
• Clinical-grade versus consumer testing: a direct-to-consumer report may include PLA2G7 variants but may use less rigorous calling methods. Confirmatory testing through a clinical lab is appropriate if a result will change a meaningful health decision.